Anixa reports updated survival data from Phase 1 lira-cel ovarian cancer CAR-T trial

Anixa Biosciences, Inc. - Common Stock

Anixa Biosciences, Inc. - Common Stock

ANIX

0.00
  • Anixa Biosciences reported updated survival observations from its ongoing Phase 1 trial of lira-cel, an FSHR-targeted CAR-T therapy for recurrent ovarian cancer.
  • Results were presented May 7, 2026, at International Society for Cell & Gene Therapy 2026 Annual Meeting.
  • Several treated patients have lived substantially longer than typically expected for this advanced setting, with multiple patients remaining alive on follow-up.
  • Early safety profile remained favorable, supporting continued dose escalation.
  • Next cohort is expected to test a higher dose and add lymphodepletion chemotherapy to potentially improve CAR-T activity.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605110855PR_NEWS_USPR_____LA55558) on May 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.